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ABSTRACT: Since loss of function mutations of PINK1 lead to early-onset Parkinson’s disease, there has been growing 
interest in the discovery of small molecules that amplify the kinase activity of PINK1. We herein report the design, 
synthesis, serum stability and hydrolysis of four kinetin riboside ProTides. These ProTides, along with kinetin riboside, 
activated PINK1 in cells independent of mitochondrial depolarization. This highlights the potential of modified 
nucleosides and their phosphate prodrugs as treatments for neurodegenerative diseases.
Parkinson’s disease (PD) is the second most common 
neurodegenerative disease in the world.1 It affects around 
130,000 people in the UK and over 1 million people in the 
USA.1 Considering that current PD therapies and medical 
interventions are limited only to addressing the symptoms 
of this disease2 coupled with a general rise in lifespan, the 
rate of PD-incidence in the future is likely to increase 
significantly. This highlights the need for new and specific 
PD treatments. As part of our efforts into discovering novel 
PD therapeutics, we focused on PINK1 (PTEN-induced 
kinase 1), a protein kinase mutated in some patients with 
early-onset PD.3 
PINK1 is a mitochondrial Serine/Threonine protein kinase 
that possesses a unique N-terminal mitochondrial 
targeting sequence, a transmembrane domain and three 
insertional loops within its catalytic kinase domain.4 
Following inner mitochondrial membrane depolarization, 
it becomes stabilized on the outer mitochondrial 
membrane (OMM) where it phosphorylates the E3 
ubiquitin ligase Parkin at Serine  65 (Ser65) on its N-
terminal ubiquitin-like domain. Such phosphorylation 
activates Parkin, which is also mutated in early-onset PD,5 
leading to the ubiquitylation of a series of its substrates on 
the OMM that act as a signal for the degradation of 
mitochondria by autophagy (mitophagy).6  
In PD, the majority of PINK1 mutations are located within 
its kinase domain and consequently affect its catalytic 
activity.7,8 This confirms that the kinase activity of PINK1 is 
critical to the prevention of neurodegeneration. This 
notion has been verified in Drosophila models of PINK1 in 
which kinase-inactive versions of PINK1 failed to rescue 
neurodegeneration compared to the wild-type gene.9 
Hence, the activation of PINK1 emerged as a useful strategy 
to induce and maintain neuroprotective effects, an 
approach that would be useful in treating PD. 
To date, reported efforts into the discovery of small 
molecules that activate PINK1 led to the identification of 
N6-furfuryladenine, termed kinetin (1, Figure 1),10 which is 
undergoing clinical trials for the treatment of  Familial 
Dysautonomia and the prevention from skin 
photodamage.11 In cells, pronounced activation of PINK1 by 
kinetin was only observed following co-incubation with 
the mitochondria-depolarizing agent CCCP (carbonyl 
cyanide m-chlorophenyl hydrazine),5 which in itself 
activates PINK1 in cells.12 Studies into the mechanism by 
which PINK1 is activated by kinetin revealed that kinetin 
was converted intracellularly in four consecutive metabolic 
 steps to the active metabolite kinetin riboside (KR) 
triphosphate 4, which acts as a PINK1 ATP-neosubstrate 
(Figure 1).10 
 
 
 
 
 
 
 
 
 
Figure 1. Chemical structure of kinetin (1) and its 
metabolism in cells to generate the active substrate kinetin 
riboside triphosphate (4). 
 
Given that the cellular activation of synthetic nucleobases 
and their nucleoside derivatives may be of limited 
efficiency as compared to natural nucleobases and 
nucleosides, we explored the direct use of the KR 
monophosphate intermediate (3) as an activator of PINK1. 
Using this metabolite, 3, instead of kinetin to activate 
PINK1 in cells would bypass two important activation 
steps, glycosylation and the first phosphorylation step, that 
kinetin must undergo consecutively. This suggests that KR 
monophosphate would be a more potent activator of PINK1 
than kinetin. As nucleoside monophosphates often have 
poor in vivo stability and inefficient cellular uptake, we 
employed the ProTide prodrug technology13, to deliver KR 
monophosphate into cells. This prodrug technology has 
inspired the discovery of two FDA-approved (antiviral) 
nucleotide monophosphate and monophosphonate drugs 
with many more undergoing clinical trials.14  
The synthesis of KR ProTides started by making kinetin 
riboside in a single step from 6-chloropurine riboside (10) 
as reported (Figure 2).15 This involved refluxing 6-
chloropurine riboside with furfurylamine in ethanol in the 
presence of triethylamine. The pure product was 
subsequently coupled16 with the appropriate 
phosphorochloridate (6-9) in the presence of tBuMgCl or 
NMI as a base to afford the desired KR ProTides (11-14).  
Figure 2. Synthesis of kinetin riboside and its ProTides. 
Reagents and conditions: (i) POCl3, TEA, Et2O, -78 °C; (ii) 
L-alanine ester hydrochloride, TEA, DCM, -78 °C; (iii) 
Furfurylamine, TEA, EtOH, N2, 77 °C, (iv) tBuMgCl or NMI, 
DCM, N2, rt. 
In the design of these ProTides, the amino acid of the 
ProTides was fixed as L-alanine since this historically17 has 
given the optimum biological activity and is processed well 
by enzymes during the metabolism of the ProTides in vivo. 
A small selection of ester motifs was used in this study 
[methyl (Me), isopropyl (iPr), tert-butyl (tBu) and benzyl 
(Bn)] to probe the influence of these moieties on the 
ProTides’ biological activity.  
Since these ProTides are prodrugs aimed at delivering KR 
monophosphate, we initially explored the hydrolysis of the 
phosphate masking groups to release the naked KR 
monophosphate. The intracellular metabolism18 of 
ProTides is known to be triggered by esterase enzymes, 
such as cathepsin A,19 which cleave off the ester motif 
(Figure 3). The generated carboxylate group (15) undergoes 
a nucleophilic attack on the phosphate group resulting in 
the loss of the phenyl group and the formation of an 
unstable 5-membered heterocyclic ring (16). A water 
molecule subsequently attacks the phosphate group to 
open this ring and generate metabolite 17. Finally, a 
phosphoramidase-type enzyme, e.g. Hint-1,20-22 hydrolyses 
the P-N bond of metabolite 17 leading to the release of the 
KR monophosphate. 
Figure 3. Postulated mechanism of in vivo metabolism of 
ProTides to release nucleoside analogue monophosphates. 
To probe the hydrolysis of KR ProTides to release KR 
monophosphate, we followed the hydrolysis of the KR 
ProTide 14 by 31P-NMR in the presence of recombinant 
cathepsin A (Figure 4A).16 We chose KR ProTide 14 as it has 
an L-alanine isopropyl moiety akin to the two ProTides 
approved for use in the clinics, e.g. Sofosbuvirâ and 
Tenofovir alafenamide, which both bear the same L-
alanine isopropyl ester moiety.17 Before the addition of the 
enzyme, ProTide 14 (in d6-acetone) showed two peaks (δP 
3.58 and 3.88) corresponding to its two diastereoisomers. 
After ~ 15 minutes incubation with cathepsin A in TRIZMA 
buffer, two peaks at δP 3.7 and 4.1 appeared, which 
correspond to the parent ProTide diastereoisomers under 
the d6-acetone/TRIZMA buffer. After ca. 2 h, a new peak at 
δP 6.81 started appearing. This corresponds to metabolite 
17 in agreement with previous reports.16 Following 12 h, 
almost all of ProTide 14 was converted to metabolite 17 and 
post 48 h incubation a new peak, δP - 0.11, appeared, a 
typical 31P-NMR shift of nucleoside monophosphates. 
	
 Indeed, negative ion electrospray ionization mass spec 
analysis of the sample showed that this new peak had a 
mass of 426.1 g/mol, which matches the mass of KR 
monophosphate 3 (MW = 427.31 g/mol) (Supplementary 
figure S1). Although in this sample, there was no 
phosphoramidase-type enzyme, e.g. Hint-1, that cleaves 
the P-N bond of intermediate 17 to generate the 
monophosphate species, it appears that the P-N bond of 
metabolite 17 was unstable under the assay condition after 
> 48 h incubation. Together, the data indicated that 
incubation of a KR ProTide with cathepsin A triggered its 
hydrolysis to the major metabolite 17 with a trace of KR 
monophosphate. 
 
Figure 4. Metabolism and serum stability of KR ProTides. 
(A) 31P-NMR of cathepsin A mediated in vitro degradation 
of KR ProTide 14. (B) Docking of metabolite 17 into the 
crystal structure of Hint-1 to predict the cleavage of the P-
N bond. (C) Stability of KR ProTide 14 in human serum 
over 12 hr as monitored by 31P-NMR. 
 
To verify whether the kinetin riboside amidate 17 would be 
a good substrate for the carboxypeptidase Hint-1, which 
cleaves the P-N bonds of phosphoramidates,20-22 we 
performed in silico docking of metabolite 17 into the co-
crystal structure of Hint-1 with AMP (Figure 4B). Analysis 
of the different predicted poses indicated that the KR 
nucleobase was stabilized by hydrophobic interactions 
with two phenylalanine residues (F19 and F41) as well as 
isoleucine (I44). Critically, the phosphate moiety was 
placed where the phosphate group of AMP was located 
while the phosphoramidate motif was positioned in a 
pocket that included the key amino acid residues required 
for the Hint-1 catalytic activity (Serine 107, Histidines 112 
and 114). Such position suggests that metabolite 17 is likely 
to be processed by Hint-1 to release KR monophosphate in 
agreement woth previous conclusions.16 
Subsequently, we examined the stability of KR ProTides in 
human and mouse serum in situ. For this, we incubated KR 
ProTide 14 in either human (Figure 4C) or mouse serum 
(Supplementary figure S2) at 37 °C and followed the sample 
by 31P NMR. At t = 0, two close 31P NMR signals, δP 4.0 and 
4.5 ppm corresponding to the two diastereoisomers of KR 
ProTide 14 were present. The time-course 31P NMR 
revealed that no new peaks appeared that may correspond 
to new metabolites. Indeed, following ca. 11 h incubation in 
human and mouse serum there was no changes in the 31P 
NMR signals that correspond to the KR ProTide indicating 
its stability in these environments. Additionally, we 
studied the stability of KR ProTides in acid environment. 
For this, we incubated ProTide 14 in acidic buffer, pH = 1, 
and monitored it by 31P NMR over 12 h. The data showed 
that the ProTide was completely stable in this acidic 
environment, pH = 1, since the phospho peaks 
corresponding to ProTide 14 persisted throughout the 12 h 
period studied (Supplementary figure S3). 
Once the hydrolysis and stability of KR ProTides were 
established, we then investigated their ability to activate 
PINK1 in cells. Briefly, HEK293 Flp-In TRex HEK293 cells 
stably expressing wild-type PINK1 were co-transfected with 
untagged wild type Parkin. Upon activation, PINK1 directly 
phosphorylates Parkin at Ser65,23 and this phosphorylation 
site was used as a read out for the activity of PINK1 in cells. 
Initially, the cells were treated with 50 µM of kinetin, KR 
or KR ProTides (11-14) for 24 h (Fig. 5). 
Figure 5. Activation of PINK1 by KR ProTides in cells. Flp-
In TRex HEK293 cells stably expressing PINK1 were co-
transfected with wild-type. Cells were treated with 50 μM 
KR ProTides 11-14, kinetin or kinetin riboside for 24 h. Cells 
were then lysed and probed with anti-phospho Ser65 Parkin 
(pS65 Parkin), total parkin, PINK1 and Vinculin antibodies. 
*NS: non-specific band.  
 
Interestingly three out of the four KR ProTides showed 
activation of PINK1, as judged by Parkin Ser65 
phosphorylation in the absence of CCCP treatment. KR 
ProTide 13 exhibited the most significant activation 
followed by ProTides 14 and 11. Notably, KR also showed 
significant activation of PINK1 while treatment with 
kinetin did not lead to noticeable PINK1 activation in the 
absence of CCCP.  
The activation of PINK1 by KR ProTides indicates that they 
ProTides were metabolized to release KR monophosphate, 
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 which was then further phosphorylated to the active 
triphosphate counterpart to act as a PINK1 ATP-
neosubstrate. This possibility is supported by the lack of 
PINK1 activation with KR ProTide 12, which has the tBu 
ester motif that is known to be poorly metabolized in vivo 
by esterases as compared to ProTides with Me, iPr and Bn 
esters.13 In fact, in vitro cathepsin A hydrolysis of KR 
ProTide 12 was very slow following 12 h incubation with the 
esterase enzyme cathepsin A as ca. 50% of the parent 
ProTide remained intact (Supplementary figure S4) in 
contrast to ProTide 14, which was rapidly hydrolyzed 
(Figure 5A). The fact that KR showed comparable PINK1 
activation to KR ProTides suggests that the first 
phosphorylation step by which KR is converted into its 
monophosphate species, and which is by-passed by the 
ProTides, is not the aret limiting step is its activation. This 
is seen with other therapeutic nucleosides such as 
lamivudine and zidovudine for which the first 
phosphorylation step is not the rate-limiting in their 
activation, but the second or the third phosphorylation 
steps.24  
Since the activation of PINK1 by KR and its ProTides was 
determined after 24 h incubation (Figure 5), we next 
determined the time-dependent activation of PINK1 in 
cells by the most potent KR ProTide activator of PINK1, 13. 
Under similar conditions, we treated cells with ProTide 13 
for 3, 6, 12, 24 and 48 h (Figure 6). The data shows that KR 
ProTide 13 activated PINK1 in a time-dependent manner 
with the most prominent activation observed after 24 h 
treatment. The activation, however, was not as significant 
as achieved with CCCP and no phosphorylation of Parkin 
was detected in cells expressing the Parkin S65A mutant as 
expected. 
 
Figure 6. Time-dependent activation of PINK1 by KR 
ProTide 13 in Flp-In TRex HEK293 cells stably expressing 
PINK1 transfected with wild-type. Experiment was 
performed as in Figure 5. 
 
In conclusion, we herein described the first application of 
the powerful ProTide phosphate prodrug technology to 
elaborate nucleoside-based molecules that activate PINK1 
in cells. Of the four KR ProTides synthesised and studied 
in this work, three KR ProTides showed activation of the 
kinase activity of PINK1 with KR ProTide 13 exhibiting the 
highest potency. Uniquely, this activation was 
independent of CCCP, a mitochondrial depolarizing agent, 
which has been used previously10 in identifying kinetin as 
an activator of PINK1. In view of the ability of these KR 
ProTides to activate PINK1, it may be promising to 
optimize these further as potential neuroprotective agents 
for PD. Such endeavour is supported by the favorable 
human and mouse serum stability profiles of these 
ProTides in addition to their encouraging stability in acidic 
environments. Notably, our approach of using the ProTide 
technology in developing protein kinase activators has the 
potential to be expanded to the discovery of ATP-
neosubstrates for other protein kinases beyond PINK1 and 
neurodegeneration. 
EXPERIMENTAL SECTION 
General information. Dichloromethane, diethyl ether, 
methanol and toluene were dried in-house using a Pure Solv-MD 
Solvent Purification System. All the other solvents were used as 
received from commercial suppliers. All of the other reagents 
used in the synthesis were purchased from Sigma-Aldrich except 
L-alanine isopropyl ester. All reactions were carried out under an 
argon atmosphere. Reactions were monitored with analytical TLC 
on Silica Gel 60-F254 pre-coated aluminum plates and visualized 
under UV (254 nm) and/or with 31P NMR spectra. Column 
chromatography was performed on silica gel (35–70 µM). NMR 
data were recorded either on a Bruker AV300, AVIII300, AV400, 
AVIII400 or DRX500 spectrometers in the deuterated solvents 
indicated and the spectra were calibrated on residual solvent 
peaks. Chemical shifts (δ) are quoted in ppm and J values are 
quoted in Hz. In reporting spectral data, the following 
abbreviations were used: s (singlet), d (doublet), t (triplet), q 
(quartet), dd (doublet of doublets) and m (multiplet). HPLC was 
carried out on a DIONEX summit P580 quaternary low pressure 
gradient pump with a built-in vacuum degasser using a Summit 
UVD 170s UV/Vis multichannel detector. Solvents were used as 
HPLC grade. Chromeleon software was used to visualize and 
process the obtained chromatograms. Analytical separations used 
a flow rate of 1 mL/min, and semi-preparative used a flow rate of 
3 mL/min and preparative used a flow rate of 20 mL/min. All 
tested compounds had a purity of ≥95% as shown by HPLC or 
elemental analysis (see Supporting Information).  
Kinetin Riboside (2).15 Furfurylamine (0.54 mL, 6.2 mmol) and 
Et3N were added dropwise to a suspension of 6-chloropurine 
riboside6 10 (600 mg, 2.1 mmol) in EtOH (30mL). This was 
refluxed for 18 h at 60 °C. The resulting yellow solution was 
evaporated under reduced pressure to yield the crude mixture as 
a cream paste. This was washed with Et2O (3 x 25 mL) and filtered 
to give the product as a white crystalline solid (679 mg, 93%); 1H 
NMR (400 MHz, MeOD) δ 8.26 (2H, s, H-2/H-8), 7.43 (1H, dd, J = 
1.9, 0.9 Hz, CH2ArO-H), 6.34 (1H, dd, J = 3.2, 1.8 Hz, CH2ArO-H), 
6.31 (1H, dd, J = 3.2, 0.9 Hz, CH2ArO-H), 5.95 (1H, d, J = 6.4 Hz, 1’-
H), 4.80 (2H, s, NH2CH2), 4.74 (1H, dd, J = 6.4, 5.1 Hz, 2’-H), 4.31 
(1H, dd, J = 5.1, 2.5 Hz, 3’H), 4.16 (1H, q, J = 2.5 Hz, 4’-H), 3.81 (2H, 
ddd, J = 57.3, 12.6, 2.6 Hz, 5’-H2); 13C NMR (100 MHz, MeOD) 152.0 
(C-8/C-2), 151.6 (CH2ArO-C), 149.6, 147.8 (ArN-C), 142.0 (CH2ArO-
CH), 140.3 (C-8/C-2), 119.9 (ArN-C), 110.0 (CH2ArO-CH), 106.9 
(CH2ArO-CH), 89.9 (1’-C), 86.8 (4’-C), 74.0 (2’-C), 71.3 (3’-C), 62.1 
(5’-C), 36.7 (NHCH2); MS-ESI (m/z): C15H17N5O5 [M + Na]+ 370.1. 
Phenyl-(methoxy-L-alaninyl)-phosphorochloridate (6).16 L-
alanine methyl ester hydrochloride (400 mg, 2.9 mmol) was 
dissolved in anhydrous CH2Cl2 (20 mL) under an inert 
atmosphere. Following this, phenyl phosphorodichloridate (0.53 
mL, 2.9 mmol) was added dropwise over 15 min. Et3N (0.77 mL, 
5.8 mmol) was then added at -78 °C and the mixture was stirred 
for 30 min. The solution was then allowed to warm up to room 
temperature over 2 h. Solvent was then removed under reduced 
pressure and the remaining white precipitate suspended in 
anhydrous Et2O (50 mL). This was filtered and the filtrate 
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 evaporated under reduced pressure, yielding the crude product as 
a light brown oil. Purification via flash column chromatography 
gave the pure product as a colourless oil (729 mg, 91%); (Eluent 
7:3 EtOAC:hexane); 31P NMR (120 MHz, CDCl3) δ 7.94, 7.62; 1H 
NMR (400 MHz, CDCl3) δ 7.45-7.33 (2H, m, Ar-H), 7.31-7.21 (3H, 
m, Ar-H), 4.62-4.52 (1H, m, N-H), 4.26-4.14 (1H, m, CHCH3), 3.79, 
3.77 (2H, 2 s, OCH3), 1.51 (3H, dd, J = 7.1, 4.1 Hz, CHCH3);  13C NMR 
(100 MHz, CDCl3) δ 173.4 (COCH3), 150.1 (Ar-COP), 130.3, 126.4, 
121.0 (Ar-CH), 53.3 (OCH3), 51.1 (CHCH3), 20.9 (CHCH3). 
Phenyl-(tert-butyloxy-L-alaninyl)-phosphorochloridate 
(7).16  Prepared as described for compound 6 using L-alanine tert-
butyl ester hydrochloride (400 mg, 2.20 mmol), phenyl 
phosphorodichloridate (0.30 mL, 2.20 mmol) and Et3N (0.60 mL, 
4.4 mmol). Product 7 was obtained as a pale yellow oil, which was 
used in sequential steps without further purification (803 mg, 
114%). 31P NMR (120 MHz, CDCl3) δ 8.26, 7.84; 1H NMR (400 MHz, 
CDCl3) δ 7.44 -7.32 (2H, m, Ar-H), 7.30-7.20 (3H, m, Ar-H), 4.28 
(1H, br s, NH), 4.12-3.98 (1H, m, CHCH3), 1.56-1.34 (3H, m, CHCH3, 
9H, m, OCtBu); 13C NMR (100 MHz, CDCl3) δ 171.9 (COCOtBu), 
149.9 (Ph-COP), 130.0, 126.1, 120.1 (Ph-CH), 82.9 (OCtBu), 51.0 
(CHCH3), 28.1 (OCtBu), 20.8 (CHCH3). 
Phenyl-(benzyloxy-L-alaninyl)-phosphorochloridate (8).16 
Prepared as described for compound 6 using L-alanine benzyl 
ester hydrochloride (500 mg, 2.32 mmol), phenyl 
phosphorodichloridate (0.35 mL, 2.32 mmol) and Et3N (0.63 mL, 
4.64 mmol). Product 8 was obtained a pale yellow oil (505 mg, 
95%). 31P NMR (120 MHz, CDCl3) δ 7.85, 7.49; 1H NMR (400 MHz, 
CDCl3) δ 7.40-7.32 (m, 5H, Ph-H), 7.28-7.21 (m, 5H, Ph-H), 5.21 
(2H, d, J = 6.1 Hz, OCH2Ph), 4.31-4.15 (2H, 2 m, CHCH3), 1.52 (3H, 
dd, J = 6.6, 2.4 Hz CHCH3); 13C NMR (100 MHz, CDCl3) δ 172.6 
(COOCH2Ph), 149.7 (Ph-C), 135.0 (Ph-C), 130.0, 128.7, 128.6, 128.4, 
126.0, 120.6 (Ph-CH), 67.6 (OCH2Ph), 50.8 (CHCH3), 20.6 
(CHCH3). 
Phenyl-(isopropoxy-L-alaninyl)-phosphorochloridate (9).16 
Prepared as described for compound 6 using L-alanine isopropyl 
ester hydrochloride (700 mg, 4.18 mmol), phenyl 
phosphorodichloridate (0.62 mL, 4.18 mmol) and Et3N (1.13 mL, 
8.36 mmol). Product 9 was obtained as a yellow oil (1185 mg, 93%). 
31P NMR (120 MHz, CDCl3) δ 8.10, 7.80; 1H NMR (400 MHz, CDCl3) 
δ 7.46-7.32 (2H, m, Ar-H), 7.30-7.19 (3H, m, Ar-H), 5.16-5.00 (1H, 
m, OCHiPr), 4.50-4.30 (1H, m, N-H), 4.22-4.03 (1H, m, CHCH3), 
1.52-1.47 (3H, m, CHCH3), 1.32-1.22 (6H, m, OCHiPr); 13C NMR (100 
MHz, CDCl3) δ 172.2 (COCH3), 149.9 (Ar-COP), 130.0, 126.1, 120.7 
(Ar-CH), 69.8 (OCHiPr), 50.8 (CHCH3), 21.8 (2C, OCHiPr), 20.6 
(CHCH3). 
Phenyl-(methoxy-L-alaninyl) kinetin riboside 
phosphoramidate (11). KR 2 (200 mg, 0.60 mmol) was 
suspended in anhydrous THF (15 mL) under an inert atmosphere. 
To this, tBuMgCl (0.09 mL, 0.68 mmol) was then added dropwise 
over 15 min. The resulting solution was stirred for 10 min and 
following this, 6 (241 mg, 0.86 mmol) in anhydrous THF (1.5 mL) 
was then added dropwise over 10 min. The mixture was left to stir 
for 18 h. MeOH (2 mL) was then added to quench the reaction 
before solvent being removed under reduced pressure to leave the 
crude product as a pale yellow oil. This was purified via flash 
column chromatography and then preparative TLC to yield the 
final product as a white solid (34 mg, 10%); (Eluent 3:97 to 5:95 
MeOH:CH2Cl2); δ 31P NMR (120 MHz, MeOD) δ 3.84, 3.69;  1H 
NMR (400 MHz, MeOD) δ 8.27 (1H, s, ArN-CH), 8.23, 8.20 (1H, 2 
s, ArN-CH), 7.43 (1H, m, CH2ArO-H), 7.30 (2H, t, J = 7.9 Hz, Ph-
H), 7.22-7.12 (3H, m, Ph-H), 6.34 (1H, dd, J = 3.4, 1.8 Hz, CH2ArO-
H), 6.32 (1H, d, J = 2.8 Hz, CH2ArO-H), 6.04 (1H, t, J = 5.0 Hz, 1’-
H), 4.80 (2H, br s, NHCH2), 4.70-4.60 (1H, m, 2’H),  4.46-4.30 (3H, 
m, 3’H/5’H2), 4.29-4.23 (1H, m, 4’-H), 3.95-3.77 (2H, 2 m, CHCH3), 
3.61 (3H, s, OCH3), 1.30-1.27 (3H, m, CHCH3); 13C NMR (100 MHz, 
MeOD) δ 175.5 (COOCH3), 154.0 (ArN-CH), 153.4 (ArO-C), 152.1 
(Ph-C), 150.3 (ArN-C), 143.4 (ArO-CH), 140.7 (ArN-CH), 130.7, 
126.2, 121.9 (Ph-CH), 120.9 (ArN-C), 111.4, 108.2 (ArO-CH), 90.0 (1’-
C), 84.4 (4’-C), 75.4 (2’-C), 71.6 (3’-C), 67.3 (5’-C), 52.7 (OCH3), 51.4 
(CHCH3), 38.4 (NHCH2), 20.3 (CHCH3); HRMS-ESI (m/z): Calc. 
for C25H29N6O9NaP [M + Na]+ 611.1631, found 611.1633; Found: C 
51.2, H 5.3, N 14.2 Calc. for C25H29N6O9P: C 51.0, H 4.97, N 14.3 %.  
Phenyl-(tert-butyloxy-L-alaninyl) kinetin riboside 
phosphoramidate  (12). Prepared as described for compound 11 
KR 2 (200 mg, 0.60 mmol), NMI (0.22 mL, 3.00 mmol) and 7 (552 
mg, 1.80 mmol). The crude product was purified via flash column 
chromatography to yield the final product as a white solid (52 mg, 
14%); (Eluent 3:97 to 5:95 MeOH:CH2Cl2); 31P NMR (120 MHz, 
MeOD) δ 3.91, 3.84;  1H NMR (400 MHz, MeOD) δ  8.22 (1H, s, 
ArN-CH), 8.22, 8.19 (1H, 2 s, ArN-CH), 7.43 (1H, dd, J = 1.9, 0.9 Hz, 
CH2ArO-H), 7.35-7.26 (2H, m, Ph-H), 7.21-7.10 (3H, m, Ph-H), 6.34 
(1H, dd, J  = 3.2, 1.9 Hz, CH2ArO-H), 6.32-6.30 (1H, m, CH2ArO-H), 
6.05-6.02 (1H, m, 1’-H), 4.79 (2H, s, NHCH2),  4.65 (1H, t, J = 5.2 
Hz, 2’H), 4.48-4.30 (3H, m, 3’-H/5’H2), 4.29-4.24 (1H, m, 4’-H), 
3.82-3.75 (1H, m, CHCH3), 1.39 (9H, s, t-Bu-H), 1.23 (3H, dd, J = 7.1, 
1.2 Hz, CHCH3); 13C NMR (100 MHz, MeOD) δ 172.9 (CO), 154.3 
(ArN-C), 152.6 (ArNC-H), 151.8 (ArO-C), 150.7 (PhCOP), 148.6 
(ArN-C), 142.0 (ArOC-H), 139.3 (ArNC-H), 129.4, 124.7, 120.0 (PhC-
H), 119.2 (ArN-C), 110.0, 106.8 (ArOC-H), 88.6 (1’-C), 83.0 (4’-C), 
81.2 (OCtBu), 74.0 (2’-C), 70.2 (3’-C), 65.7 (5’-C), 50.8 (CHCH3), 37.1 
(NHCH2), 26.8 (3C, OCtBu), 19.1 (CHCH3); HRMS-ESI (m/z): Calc. 
for C28H35N6O9NaP [M + Na]+ 653.2101, found 653.2104; Found: C 
53.4, H 5.6, N 13.5 Calc. for C28H35N6O9P: C 53.3, H 5.6, N 13.3 %. 
Phenyl-(benzyloxy-L-alaninyl) kinetin riboside 
phosphoramidate (13). Prepared as described for compound 11 
using 2 (250 mg, 0.72 mmol), NMI (0.29 mL, 3.6 mmol) and 8 (765 
mg, 2.16 mmol). The crude product was purified via flash column 
chromatography was purified via flash column chromatography 
to yield the final product as a white solid (60 mg, 13%); (Eluent 
3:97 to 5:95 MeOH:CH2Cl2); 31P NMR (120 MHz, MeOD) δ 3.89, 
3.64;  1H NMR (400 MHz, MeOD) δ 8.26 (1H, s, ArN-CH), 8.20, 
8.17 (1H, 2 s, ArN-CH), 7.41 (1H, d, J = 1.8, CH2ArO-H), 7.32-7.24 
(7H, m, Ph-H), 7.21-7.06 (3H, m, Ph-H), 6.32 (1H, dd, J = 3.3, 1.9 
Hz, CH2ArO-H), 6.29 (1H, d, J = 3.2 Hz, CH2ArO-H), 6.03 (1H, t, J 
= 4.9 Hz, 1’-H), 5.18-4.98 (2H, 2 m, CH2Ph), 4.77 (2H, br s, NHCH2), 
4.67-4.57 (1H, m, 2’-H), 4.43-4.33 (3H, m, 3’-H/4’-H/5’-H), 4.33-
4.20 (1H, m, 5’-H), 4.02-3.85 (1H, m, CHCH3), 1.25 (3H, dd, J = 19.4, 
7.0 Hz, CHCH3); 13C NMR (100 MHz, MeOD) δ 174.8 
(COOCH2Ph), 155.8 (ArN-C), 153.9 (ArN-CH), 152.0 (Ph-C), 150.2 
(ArN-C), 143.3 (ArO-CH), 140.6 (ArN-CH), 139.0 (Ph-CH), 137.1 
(Ph-C), 130.7, 129.2, 128.8, 126.2, 121.9, 121.3 (Ph-CH), 121.0 (ArN-C), 
111.4, 108.2 (ArO-CH), 89.9 (1’-CH), 84.3 (4’-C), 75.4 (2’-CH), 71.4 
(3’-CH), 67.7 (CH2Ph), 67.1 (5’-C), 51.5 (CHCH3), 38.2 (NHCH2), 
20.4 (CHCH3); HRMS-ESI (m/z): Calc. for C31H33N6O9NaP [M + 
Na]+ 687.1944, found 687.1942; Found: C 55.95, H 5.2, N 12.6. Calc. 
for C31H33N6O9P: C 56.0, H 5.0, N 12.65 %. 
Phenyl-(isopropoxy-L-alaninyl) kinetin riboside 
phosphoramidate (14). Prepared as described for compound 11 
using 2 (250 mg, 0.72 mmol), NMI (0.29 mL, 3.60 mmol) and 9 
(660 mg, 2.16 mmol). The crude product was purified via flash 
column chromatography to yield the final product as a white solid 
(185 mg, 42%); (Eluent 3:97 to 5:95 MeOH:CH2Cl2); 31P NMR (120 
MHz, CDCl3) δ 3.02, 2.86;  1H NMR (400 MHz, CDCl3) δ 8.27 (1H, 
s, ArN-CH), 7.98, 7.94 (1H, 2 s, ArN-CH), 7.30 (1H, dd, J = 2.5, 1.4 
Hz, CH2ArO-H), 7.15 (2H, t, J = 7.7 Hz, Ph-H), 7.07 (2H, d, J = 7.7 
Hz, Ph-H), 7.00 (1H, m, Ph-H), 6.74 (1H, br s, NHCH2ArO), 6.25 
(2H, t, J = 1.7 Hz, CH2ArO-H), 5.98 (1H, t, J = 4.4 Hz, 1’-H), 5.38 
(1H, br s, O-H), 4.96-4.85 (1H, m, OCHiPr), 4.78 (2H, br s, 
NHCH2ArO), 4.57-4.25 (6H, m, NHCHCH3, 2’-H, 3’-H, 4-H, 5’-H2), 
3.94-3.81 (1H, m, NHCHCH3), 1.24 (3H, t, J = 7.2 Hz, NHCHCH3), 
1.19-1.05 (6H, m, OCHiPr); 13C NMR (100 MHz, CDCl3) δ 172.9 
(CO), 154.0 (ArNC), 152.6 (ArNC-H), 151.4 (ArO-C), 150.2 (Ph-C), 
148.5 (ArNC), 142.0 (ArO-CH),  138.6 (ArNC-H),  129.4 (Ph-CH), 
124.7 (Ph-CH), 119.8 (Ph-CH), 119.6 (ArNC), 110.6 (ArO-CH), 107.3 
 (ArO-CH), 88.9 (1’-C), 83.1 (4’-C), 74.5 (2’-C), 70.4 (3’-C) 68.9 
(OCHiPr), 65.8 (5’-C), 50.0 (NHCHCH3), 37.2 (NHCH2ArO), 21.4 
(OCHiPr), 20.5 (NHCHCH3); HRMS-ESI (m/z): Calc. for 
C27H34N6O9P [M + H]+ 617.2125, found 617.2144; HPLC CH3CN:H2O 
0:100 to 100:0 in 30 min, λ = 254 nm, tR 16.51, 16.69 min. 
Cathepsin A Assay. Procedure adapted from Mehellou et al., 
2010.16 ProTide 14 (5.0 mg) was dissolved in acetone-d6 (0.15 mL), 
followed by addition of Trizma buffer (0.30 mL, pH 7.4). After 
recording a control 31P NMR spectrum containing ProTide in d6-
acetone and buffer, defrosted cathepsin A (0.1 mg dissolved in 0.15 
mL of Trizma buffer), was added to the mixture. A 31P NMR was 
then run immediately after the addition and then at even time 
intervals over 11 h.  The sample was then analysed by 31P NMR after 
24 and 48 h. All 31P NMR spectra recorded at 22 °C (±1). 
Serum stability. Procedure adapted from Slusarczyk M. et al. 
2014.25 ProTide 14 (5.0 mg) was dissolved in DMSO-d6 (0.10 mL) 
and D2O (0.15 mL). All 31P NMR spectra were recorded at 37 °C. 
Two control spectra were recorded, one containing ProTide 14 
(5.0 mg) in DMSO-d6 (0.10 mL) and D2O (0.15 mL) and the other 
containing defrosted human serum (0.3 mL), DMSO-d6 (0.10 mL) 
and D2O (0.15 mL). Following this, a previously defrosted serum 
(human or mouse) (0.30 mL) was added to the NMR tube and a 
spectrum immediately run. Spectra were recorded at 30 min after 
the addition and then at even time intervals over 11 h. 
Acid Stability. Procedure adapted from Slusarczyk M. et al. 
2014.25 To ProTide 12 (5 mg) in methanol-d4 (0.25 mL) was added 
acidic buffer, pH 1 (prepared from equal parts of 0.2 M HCl and 
0.2 M KCl). The sample was then subjected to 31P NMR 
experiments at 37 °C and the spectra were recorded every 20 min 
over 12 h. 
Docking studies. PC windows 7 with Intel Core i7-4790 /3.6GHz 
microprocessor, 16 GB RAM and 64 Bit operating system was used 
to execute the computational studies. Docking was performed 
applying the molecular modelling modules namely Omega2, 
FRED and VIDA provided by OpenEye Scientific Software 
(http://www.eyesopen.com). The three-dimensional crystal 
structure of the co-crystallized AMP with the Human HINT1 was 
retrieved from the Protein Data Bank (PDB ID: 1KPF)26 and the 
active site was subsequently identified on the basis of the bound 
ligand. Multiple conformers for metabolite 17 were generated by 
Omega2 using the default settings.27 FRED (fast rigid exhaustive 
docking) implements a rigid docking approach to fit these 
conformers into the pre-defined binding site and rank the poses 
by scoring functions.28,29 The VIDA module was then used to 
visualize and inspect the docked poses within the receptor’s active 
site as well as to identify the main interacting residues. 
Cell studies. Flp-In T-Rex HEK293 cells stably expressing PINK1-
FLAG wild-type were generated previously.23 Cells were 
maintained in DMEM (Dulbeco’s modified Eagle’s medium) 
supplemented with 10 % (v/v) foetal bovin serum, 2 mM L-
glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin, plus 
15 μg/ml blasticidin and 100  μg/ml hygromycin at 37 °C under a 5 
% CO2 atmosphere. On day 0, cells were seeded in DMEM. One 
day 1, Cells were transiently transfected with wild type or S65A 
Parkin using polyethylenimine (Polysciences) according to the 
manufacturer’s instruction. One day 2, PINK1-FLAG 
overexpression was induced by adding 0.1 μg/ml doxycycline in 
DMEM for 24 h before treating cells with compounds or 
mitochondrial uncoupler, CCCP, as indicated in the figure 
legends. All compounds were dissolved in DMSO. 
Sample preparation and immunoblotting. This was carried 
out as we reported previously23. Lysis buffer used: 50 mM Tris–
HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 1 % (w/v) Triton, 1 mM 
sodium orthovanadate, 10 mM sodium glycerophosphate, 50 mM 
sodium fluoride, 10 mM sodium pyrophosphate, 0.25 M sucrose, 
0.1 % (v/v) 2-mercaptoethanol, 1 mM benzamidine, 0.1 mM PMSF 
and protease inhibitor cocktail (Roche). Antibodies used: mouse 
monoclonal anti-PINK1 antibody (human PINK1 residues 125-539) 
was raised by Dundee Cell Products, anti-vinculin and anti-
GAPDH antibodies were obtained from Cell Signaling 
Technology, anti-Parkin phospho-Serine 65 rabbit monoclonal 
antibody was raised by Epitomics in collaboration with the 
Michael J Fox Foundation for Research, anti-Parkin mouse 
monoclonal antibody was obtained from Santa Cruz. 
ASSOCIATED CONTENT  
Supporting Information. 1H NMR and 13C NMR spectra, HPLC 
data and the mass spectra of the cathepsin A sample. This material 
is available free of charge via the Internet at http://pubs.acs.org.  
AUTHOR INFORMATION 
Corresponding Authors 
*M.M.K.M.: Phone: +44(0)1382388377. E-mail: 
m.muqit@dundee.ac.uk. 
 *Y.M. : Phone: +44(0)2920875821. E-mail: 
MehellouY1@cardiff.ac.uk. 
 
Notes 
The authors declare no conflict interests. 
Author Contributions 
The manuscript was written by YM and all the authors 
provided comments and gave approval to the final version of 
the manuscript. ‡These authors contributed equally.  
ACKNOWLEDGMENT 
M.M.K.M. is funded by a Wellcome Trust Senior Research 
Fellowship in Clinical Science (101022/Z/13/Z), the Medical 
Research Council; Parkinson’s UK; the Michael J. Fox 
Foundation; J. Macdonald Menzies Charitable Trust Prize 
Studentship, Biotechnology and Biological Sciences Research 
Council; and the EMBO Young Investigator Programme.    
ABBREVIATIONS 
CCCP, carbonyl cyanide m-chlorophenyl hydrazine; DCM, 
dichloromethane; Et2O, diethyl ether; Et3N, triethylamine; 
EtOH, ethanol; KR, kinetin riboside; NMI, N-
methylimidazole; OMM, outer mitochondrial membrane; PD, 
Parkinson’s disease; PINK1, PTEN-induced putative kinase 1; 
POCl3, phosphorous oxychloride; PTEN, phosphatase and 
tensin homolog; RT: room temperature; tBuMgCl, tert-butyl 
magnesium chloride; TEA, triethylamine; Trizma: 
(tris(hydroxymethyl)aminomethane). 
REFERENCES 
1. Dorsey, E. R.; Constantinescu, R.; Thompson, J. P.; Biglan, K. M.; 
Holloway, R. G.; Kieburtz, K.; Marshall, F. J.; Ravina, B. M.; 
Schifitto, G.; Siderowf, A.; Tanner, C. M. Projected number of 
people with Parkinson disease in the most populous nations, 
2005 through 2030. Neurology 2007, 68, 384-386. 
2. Rascol, O.; Payoux, P.; Ory, F.; Ferreira, J. J.; Brefel-Courbon, C.; 
Montastruc, J. L. Limitations of current Parkinson's disease 
therapy. Ann. Neurol. 2003, 53, S3-S12. 
3. Valente, E. M.; Abou-Sleiman, P. M.; Caputo, V.; Muqit, M. M.; 
Harvey, K.; Gispert, S.; Ali, Z.; Del Turco, D.; Bentivoglio, A. R.; 
Healy, D. G.; Albanese, A.; Nussbaum, R.; Gonzalez-Maldonado, 
R.; Deller, T.; Salvi, S.; Cortelli, P.; Gilks, W. P.; Latchman, D. S.; 
Harvey, R. J.; Dallapiccola, B.; Auburger, G.; Wood, N. W. 
Hereditary early-onset Parkinson's disease caused by mutations 
in PINK1. Science 2004, 304, 1158-1160. 
 4. Kazlauskaite, A.; Muqit, M. M. PINK1 and Parkin- mitochondrial 
interplay between phosphorylation and ubiquitylation in 
Parkinson's disease. FEBS J. 2015, 282, 215-223. 
5. Lucking, C. B.; Durr, A.; Bonifati, V.; Vaughan, J.; De Michele, G.; 
Gasser, T.; Harhangi, B. S.; Meco, G.; Denefle, P.; Wood, N. W.; 
Agid, Y.; Brice, A.; French Parkinson's Disease Genetics Study 
Group; European Consortium on Genetic Susceptibility in 
Parkinson's Disease. Association between early-onset 
Parkinson's disease and mutations in the Parkin gene. N. Engl. J. 
Med. 2000, 342, 1560-1567. 
6. Pickrell, A. M.; Youle, R. J. The roles of PINK1, Parkin, and 
mitochondrial fidelity in Parkinson's disease. Neuron 2015, 85, 
257-273. 
7. Song, S.; Jang, S.; Park, J.; Bang, S.; Choi, S.; Kwon, K. Y.; Zhuang, 
X.; Kim, E.; Chung, J. Characterization of PINK1 (PTEN-induced 
putative kinase 1) mutations associated with Parkinson disease 
in mammalian cells and Drosophila. J. Biol. Chem. 2013, 288, 
5660-5672. 
8. Woodroof, H. I.; Pogson, J. H.; Begley, M.; Cantley, L. C.; Deak, 
M.; Campbell, D. G.; van Aalten, D. M.; Whitworth, A. J.; Alessi, 
D. R.; Muqit, M. M. Discovery of catalytically active orthologues 
of the Parkinson's disease kinase PINK1: analysis of substrate 
specificity and impact of mutations. Open Biol. 2011, 1, 110012. 
9. Kim, Y.; Park, J.; Kim, S.; Song, S.; Kwon, S. K.; Lee, S. H.; Kitada, 
T.; Kim, J. M.; Chung, J. PINK1 controls mitochondrial 
localization of Parkin through direct phosphorylation. Biochem. 
Biophys. Res. Commun. 2008, 377, 975-980. 
10. Hertz, N. T.; Berthet, A.; Sos, M. L.; Thorn, K. S.; Burlingame, A. 
L.; Nakamura, K.; Shokat, K. M. A neo-substrate that amplifies 
catalytic activity of Parkinson's-disease-related kinase PINK1. 
Cell 2013, 154, 737-747. 
11. www.clinicaltrials.gov (accessed on March 8th, 2017). 
12. Narendra, D. P.; Jin, S. M.; Tanaka, A.; Suen, D. F.; Gautier, C. A.; 
Shen, J.; Cookson, M. R.; Youle, R. J. PINK1 is selectively 
stabilized on impaired mitochondria to activate Parkin. PLoS 
Biol. 2010, 8, e1000298.  
13. Mehellou, Y.; Balzarini, J.; McGuigan, C. Aryloxy 
phosphoramidate triesters: a technology for delivering 
monophosphorylated nucleosides and sugars into cells. 
ChemMedChem 2009, 4, 1779-1791. 
14. Thornton, P. J.; Kadri, H.; Miccoli, A.; Mehellou, Y. Nucleoside 
phosphate and phosphonate prodrug clinical candidates. J. Med. 
Chem. 2016, 59, 10400-10410. 
15. Bressi, J. C.; Choe, J.; Hough, M. T.; Buckner, F. S.; Van Voorhis, 
W. C.; Verlinde, C. L.; Hol, W. G.; Gelb, M. H. Adenosine 
analogues as inhibitors of Trypanosoma brucei 
phosphoglycerate kinase: elucidation of a novel binding mode 
for a 2-amino-N(6)-substituted adenosine. J. Med. Chem. 2000, 
43, 4135-4150. 
16. Mehellou, Y.; Valente, R.; Mottram, H.; Walsby, E.; Mills, K. I.; 
Balzarini, J.; McGuigan, C. Phosphoramidates of 2'-beta-D-
arabinouridine (AraU) as phosphate prodrugs; design, synthesis, 
in vitro activity and metabolism. Bioorg. Med. Chem. 2010, 18, 
2439-2446. 
17. Mehellou, Y. The ProTides boom. ChemMedChem 2016, 11, 1114-
1116. 
18. Saboulard, D.; Naesens, L.; Cahard, D.; Salgado, A.; Pathirana, R.; 
Velazquez, S.; McGuigan, C.; De Clercq, E.; Balzarini, J. 
Characterization of the activation pathway of phosphoramidate 
triester prodrugs of stavudine and zidovudine. Mol. Pharmacol. 
1999, 56, 693-704. 
19. Birkus, G.; Wang, R.; Liu, X.; Kutty, N.; MacArthur, H.; Cihlar, T.; 
Gibbs, C.; Swaminathan, S.; Lee, W.; McDermott, M. Cathepsin 
A is the major hydrolase catalyzing the intracellular hydrolysis 
of the antiretroviral nucleotide phosphonoamidate prodrugs GS-
7340 and GS-9131. Antimicrob. Agents Chemother. 2007, 51, 543-
550. 
20. Congiatu, C.; Brancale, A.; McGuigan, C. Molecular modelling 
studies on the binding of some protides to the putative human 
phosphoramidase Hint1. Nucleosides Nucleotides Nucleic Acids 
2007, 26, 1121-1124. 
21. Murakami, E.; Tolstykh, T.; Bao, H. Y.; Niu, C. R.; Steuer, H. M. 
M.; Bao, D. H.; Chang, W.; Espiritu, C.; Bansal, S.; Lam, A. M.; 
Otto, M. J.; Sofia, M. J.; Furman, P. A. Mechanism of activation 
of PSI-7851 and its diastereoisomer PSI-7977. J. Biol. Chem. 2010, 
285, 34337-34347. 
22. Cheng, J. L.; Zhou, X.; Chou, T. F.; Ghosh, B.; Liu, B. L.; Wagner, 
C. R. Identification of the amino acid-AZT-phosphoramidase by 
affinity T7 phage display selection. Bioorg. Med. Chem. Lett. 
2009, 19, 6379-6381. 
23. Kondapalli, C.; Kazlauskaite, A.; Zhang, N.; Woodroof, H. I.; 
Campbell, D. G.; Gourlay, R.; Burchell, L.; Walden, H.; 
Macartney, T. J.; Deak, M.; Knebel, A.; Alessi, D. R.; Muqit, M. M. 
PINK1 is activated by mitochondrial membrane potential 
depolarization and stimulates Parkin E3 ligase activity by 
phosphorylating serine 65. Open Biol. 2012, 2, 120080. 
24. Stein, D. S.; Moore, K. H. P. Phosphorylation of nucleoside 
analog antiretrovirals: a review for cinicians. Pharmacotherapy 
2001, 21, 11-34.  
25. Slusarczyk, M.; Lopez, M. H.; Balzarini, J.; Mason, M.; Jiang, W. 
G.; Blagden, S.; Thompson, E.; Ghazaly, E.; McGuigan, C. 
Application of ProTide technology to gemcitabine: a successful 
approach to overcome the key cancer resistance mechanisms 
leads to a new agent (NUC-1031) in clinical development. J. Med. 
Chem. 2014, 57, 1531-1542. 
26. Lima, C. D.; Klein, M. G.; Hendrickson, W. A. Structure-based 
analysis of catalysis and substrate definition in the HIT protein 
family. Science 1997, 278, 286-290. 
27. Hawkins, P. C.; Nicholls, A. Conformer generation with OMEGA: 
learning from the data set and the analysis of failures. J. Chem. 
Inf. Model. 2012, 52, 2919-2936. 
28. McGann, M. FRED pose prediction and virtual screening 
accuracy. J. Chem. Inf. Model. 2011, 51, 578-596. 
29. McGann, M. R.; Almond, H. R.; Nicholls, A.; Grant, J. A.; Brown, 
F. K. Gaussian docking functions. Biopolymers 2003, 68, 76-90. 
 
 
 
Kinetin riboside ProTides
Intracellular
metabolism
Intracellular
phosphorylation
PINK1
ATP neo-substrate
Mutated in 
Parkinson’s disease
proteins
1 
	
Supporting Information 
 
Kinetin riboside and its ProTides activate the Parkinson’s disease associated 
PTEN-induced putative kinase 1 (PINK1) independent of mitochondrial 
depolarisation 
Laura Osgerby, Yu-Chiang Lai, Peter J. Thornton, Joseph Amalfitano, Cécile S. Le Duff, 
Iqra Jabeen, Hachemi Kadri, Ageo Miccoli, James H. R. Tucker, Miratul M. K. Muqit,* 
Youcef Mehellou* 
 
 
 
 
 
 
I. Supplementary Figues……………………………………………………………….2-5. 
II. 1H, 13C and 31P NMR and HPLC Spectra 
1. Compound 2…………………………………………………….……………………6. 
2. Compound 6……………………………………………………………...…..……7-8. 
3. Compound 8………………………………………………………………...…..…8-9. 
4. Compound 7…………………………………………………………………....10-11. 
5. Compound 9……………………………………………………………..…..…11-12. 
6. Compound 11………………………………………………………………..…13-14. 
7. Compound 12………………………………………………………..……..….14-15. 
8. Compound 13……………………………………………………………….….16-17. 
9. Compound 14……………………………………………………………….….17-18. 
III. HPLC spectrum of 14………………………………………………………….……..19. 
 
 
 
 
 
 
 
	 2 
I. Supplementary Figures 
 
Supplementary figure S1. ESI Mass spec analysis of sample generated from the in 
vitro cathepsin A-mediated hydrolysis of KR ProTide 14. MW 426.1 g/mol corresponds to 
metabolite 17.  
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Supplementary figure S2. Stability of KR ProTide 14 in mouse serum over 12 h as 
monitored by 31P NMR. Peaks under rectangle 1 correspond the diastereoisomers of KR 
ProTide 14 while that under 2 is from the mouse serum.  
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Supplementary figure S3. Stability pf ProTide 14 in acidic environment monitored by 
31P NMR. The two peaks highlighted in the orange rectangle (dP 3.02 and 2.86) 
correspond to the two diastereoisomers of ProTide 14 in MeOD. Acidic buffer, pH = 1, 
consisted of 0.2 M HCl and 0.2 M KCl. The experiment was run at 37 °C and the sample 
was analysed by 31P NMR every 30 minutes for 12 h. A selection of the data at the 
indicated times is shown in the figure. 
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Supplementary figure S4. 31P-NMR of cathepsin A mediated in vitro degradation of KR 
ProTide 12. Figure showing KR ProTide 12 alone and then the sample after the addition 
of cathepsin A and reading at different time poinds; 10 and 30 min, 1, 4 and 11 h. 
 
 
 
 
 
 
 
 
 
 
 
 
KR	ProTide	12	alone	
	 6 
II. 1H, 13C and 31P NMR and HPLC Spectra  
 
 
 
2	
2	
	 7 
 
6	
6	
	 8 
 
 
6	
8	
	 9 
 
 
8	
8	
	 10 
 
 
 
7	
7	
	 11 
 
 
7	
9	
	 12 
 
 
 
9	
9	
	 13 
 
 
 
ProTide	11	
ProTide	11	
	 14 
 
 
ProTide	11	
ProTide	12	
	 15 
 
 
 
ProTide	12	
ProTide	12	
	 16 
 
 
 
ProTide	13	
ProTide	13	
	 17 
 
 
 
ProTide	13	
ProTide	14	
	 18 
 
 
 
ProTide	14	
ProTide	14	
	 19 
 
 
 
 
Analytical HPLC of LO-28 (ProTide 14) 
